Streetbeat News

Products Services

KMB

Schneider Electric and Kimberly-Clark have announced new Tax Credit Transfer (TCT) agreements to support grid resiliency and clean energy transition in the U.S. These agreements, facilitated by Schneider Electric, involve funding for four battery energy storage projects by Kimberly-Clark, leveraging the Inflation Reduction Act's tax credit transferability. The projects aim to advance renewable energy storage and generation, particularly in Texas.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 12:14 pm

MBRX

Moleculin Biotech presented data at IASLC 2024 on Annamycin, demonstrating significant tumor growth inhibition and extended survival in lung cancer models, with 100% non-cardiotoxicity.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 12:13 pm

RLYB

Rallybio Corporation (NASDAQ:RLYB) will present findings at the ASHG 2024 Annual Meeting showing that the risk of fetal and neonatal alloimmune thrombocytopenia (FNAIT) is more prevalent than previously thought across diverse populations.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 12:13 pm

BDTX

BHVN

VTYX

Black Diamond Therapeutics, Ventyx Biosciences, and Biohaven saw significant stock movements. Black Diamond's shares rose 54% due to positive Phase 2 data for BDTX-1535. Ventyx Biosciences announced a $27M investment from Sanofi, boosting shares by 42%. Biohaven's shares increased 26% after successful study results for Troriluzole.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 12:10 pm

SPRY

ARS Pharmaceuticals has announced that its Neffy Epinephrine Nasal Spray is now available by prescription in the U.S. This follows FDA approval for its use in treating Type I allergic reactions, including anaphylaxis.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 12:10 pm

BAK

Braskem has been selected by the U.S. Department of Energy to negotiate a $50 million award to enhance its UHMWPE production in Texas, focusing on the lithium-ion battery separator market.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 12:10 pm

AIMD

Ainos is set to begin a clinical study in Taiwan for its product VELDONA, targeting Sjögren's Syndrome. The company aims to complete all necessary regulatory approvals by Q4 2024.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 12:09 pm

ACTU

Actuate Therapeutics, Inc. has published new research on elraglusib, a GSK-3β inhibitor, highlighting its potential as an immune modulator in treating neuroblastoma. The study suggests elraglusib could activate the immune system in cancers unresponsive to checkpoint inhibitors.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 12:08 pm

ATLX

Atlas Lithium Corporation (NASDAQ:ATLX) has received a favorable recommendation from the Minas Gerais Environmental Foundation for its permit application, advancing its Neves Project towards the operation of a lithium processing plant.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 12:04 pm

CDTX

Cidara Therapeutics has initiated dosing in the Phase 2b NAVIGATE trial for CD388, a drug aimed at preventing seasonal influenza. This marks a significant step in the development of CD388, potentially impacting Cidara's future prospects.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 12:04 pm